Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27665976 | 0.86 | ALDH1A1 (0.47) | ALDH1A1HPGDTDP1CYP3A4COXFA4 | |
| SCHEMBL27700164 | 0.83 | ALDH1A1 (0.44) | ALDH1A1HPGDTDP1CYP3A4COXFA4 | |
| SCHEMBL2009830 | 0.81 | HIF1A (0.52) | ALDH1A1HPGDTDP1COXFA4MAPT | |
| SCHEMBL14139406 | 0.80 | KMT2A (0.59) | ALDH1A1COXFA4MAPTMEN1KMT2A | |
| SCHEMBL27502553 | 0.79 | ALDH1A1 (0.43) | ALDH1A1HPGDTDP1CYP3A4COXFA4 | |
| SCHEMBL4017638 | 0.78 | HIF1A (0.42) | ALDH1A1HPGDTDP1CYP3A4COXFA4 | |
| SCHEMBL6648245 | 0.78 | ALDH1A1 (0.57) | ALDH1A1HPGDTDP1CYP3A4COXFA4 | |
| SCHEMBL27212207 | 0.77 | ALDH1A1 (0.46) | ALDH1A1HPGDTDP1CYP3A4CA2 | |
| SCHEMBL5308630 | 0.76 | HIF1A (0.47) | HIF1AEPAS1 | |
| SCHEMBL8802196 | 0.76 | HIF1A (0.43) | ALDH1A1HPGDTDP1CYP3A4COXFA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101160301-B | Aminoalkyl-amidomethyl-substituted 2- (4-sulfonylamino) -3-hydroxy-3, 4-dihydro-2H-chromen-6-yl derivatives and their use as potassium channel blockers | SOLVAY PHARM BV | 2012-03-28 | — | — | CN | disclosed |
| US-7534903-B2 | Use of amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl-compounds in the treatment of cardiac arrhythmia and other disease states | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-05-19 | — | — | US | disclosed |
| US-20080113999-A1 | Use of Amidomethyl-Substituted 2-(4-Sulfonylamino)-3-Hydroxy-3,4-Dihydro-2H-Chromen-6-yl-Compounds in the Treatment of Cardiac Arrhythmia and Other Disease States | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-05-15 | — | — | US | disclosed |
| US-7368582-B2 | Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-05-06 | — | — | US | disclosed |
| CN-101160301-A | Aminoalkyl-amidomethyl-substituted 2- (4-sulfonylamino) -3-hydroxy-3, 4-dihydro-2H-chromen-6-yl derivatives and their use as potassium channel blockers | SOLVAY PHARM GMBH (DE) | 2008-04-09 | — | — | CN | disclosed |
| US-20050148659-A1 | Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148659-A1 | Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, CYP3A4 | ALDH1A1 1020/4885HPGD 771/4885TDP1 4227/4885 |
| US-20080113999-A1 | Use of Amidomethyl-Substituted 2-(4-Sulfonylamino)-3-Hydroxy-3,4-Dihydro-2H-Chromen-6-yl-Compounds in the Treatment of Cardiac Arrhythmia and Other Disease States | KCNH1, RYR2, KCNJ2 | ALDH1A1 518/4885HPGD 1732/4885TDP1 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.